Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 6/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.39 |
| ▸ | KMO | O15229 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25271191 | 0.80 | ALDH1A1 (0.39) | — | |
| SCHEMBL30488142 | 0.80 | ALDH1A1 (0.39) | — | |
| SCHEMBL4017287 | 0.79 | NOTUM (0.44) | NOTUMTSHR | |
| SCHEMBL11357632 | 0.78 | SRD5A2 (0.54) | NOTUMS1PR5S1PR1KMOTSHR | |
| SCHEMBL29456780 | 0.77 | TSHR (0.44) | NOTUMRAB9ATSHR | |
| SCHEMBL13419450 | 0.77 | TSHR (0.44) | NOTUMRAB9ATSHR | |
| SCHEMBL9370418 | 0.77 | DRD2 (0.46) | — | |
| SCHEMBL10816330 | 0.77 | ABAT (0.44) | NOTUMS1PR5S1PR1KMOTRPM5 | |
| SCHEMBL10816336 | 0.77 | ABAT (0.44) | NOTUMS1PR5S1PR1KMOTRPM5 | |
| SCHEMBL10816324 | 0.77 | ABAT (0.44) | NOTUMS1PR5S1PR1KMOTRPM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339890-A1 | AMINO ALCOHOL COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230339890-A1 | AMINO ALCOHOL COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230339890-A1 | AMINO ALCOHOL COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. | 2023-10-26 | — | — | US | disclosed |
| WO-2023107630-A2 | AMINO ALCOHOL COMPOUNDS AND USES THEREOF | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023107630-A2 | AMINO ALCOHOL COMPOUNDS AND USES THEREOF | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20220332708-A1 | SULFONAMIDE COMPOUNDS AS CARDIAC SARCOMERE ACTIVATORS | CYTOKINETICS INC (US) | 2022-10-20 | — | — | US | disclosed |
| EP-3912977-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BioMarin Pharmaceutical Inc. (US) | 2021-11-24 | — | — | EP | disclosed |
| EP-3046920-B1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARM INC (US) | 2021-08-04 | — | — | EP | disclosed |
| US-10927092-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | BIOMARIN PHARM INC (US) | 2021-02-23 | — | — | US | disclosed |
| US-20190263775-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARM INC (US) | 2019-08-29 | — | — | US | disclosed |
| US-10227323-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | BIOMARIN PHARMACEUTICAL INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20160229830-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. | 2016-08-11 | — | — | US | disclosed |
| US-20160229830-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. | 2016-08-11 | — | — | US | disclosed |
| WO-2015042397-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. (US) | 2015-03-26 | — | — | WO | disclosed |
| EP-0945438-B1 | PYRAZOLE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2003-03-05 | — | — | EP | disclosed |
| US-6057335-A | Pyrazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2000-05-02 | — | — | US | disclosed |
| EP-0945438-A1 | PYRAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10927092-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | GBA1, UGCG, GBA2 | NOTUM 770/4885S1PR5 502/4885S1PR1 342/4885 |
| US-20160229830-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | GBA1, UGCG, GBA2 | NOTUM 770/4885S1PR5 502/4885S1PR1 342/4885 |
| US-20220332708-A1 | SULFONAMIDE COMPOUNDS AS CARDIAC SARCOMERE ACTIVATORS | TNNT2, TNNI3, MYLK2 | NOTUM 2194/4885S1PR5 2582/4885S1PR1 3044/4885 |
| US-10227323-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | GBA1, UGCG, GBA2 | NOTUM 770/4885S1PR5 502/4885S1PR1 342/4885 |
| US-20190263775-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | GBA1, UGCG, GBA2 | NOTUM 770/4885S1PR5 502/4885S1PR1 342/4885 |
| US-20230339890-A1 | AMINO ALCOHOL COMPOUNDS AND USES THEREOF | AADAT, SLC1A2, SLC1A1 | NOTUM 172/4885S1PR5 1428/4885S1PR1 2217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.